Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 29% Improvement Relative Risk Mortality (b) 16% Patel et al. Vitamin C for COVID-19 LATE TREATMENT Is late treatment with vitamin C beneficial for COVID-19? Retrospective 176 patients in the USA Lower mortality with vitamin C (not stat. sig., p=0.18) Patel et al., Chest Infections, doi:10.1016/j.chest.2020.08.322 Favors vitamin C Favors control
The significance of oral ascorbic acid in patients with COVID-19
Patel et al., Chest Infections, doi:10.1016/j.chest.2020.08.322
Patel et al., The significance of oral ascorbic acid in patients with COVID-19, Chest Infections, doi:10.1016/j.chest.2020.08.322
Oct 2020   Source   PDF  
  All Studies   Meta
Retrospective 176 hospitalized patients, 96 treated with oral vitamin C (from 500mg to 1500mg daily), showing lower mortality with treatment.
Although the 29% lower mortality is not statistically significant, it is consistent with the significant 27% lower mortality [13‑38%] from meta analysis of the 34 mortality results to date.
risk of death, 29.5% lower, RR 0.71, p = 0.18, treatment 22 of 96 (22.9%), control 26 of 80 (32.5%), NNT 10.
risk of death, 15.6% lower, RR 0.84, p = 0.60, treatment 15 of 30 (50.0%), control 16 of 27 (59.3%), NNT 11, ICU patients.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Patel et al., 1 Oct 2020, retrospective, USA, peer-reviewed, 8 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin CAll
Abstract: Chest Infections SESSION TITLE: Chest Infections Posters SESSION TYPE: Original Investigation Posters PRESENTED ON: October 18-21, 2020 THE SIGNIFICANCE OF ORAL ASCORBIC ACID IN PATIENTS WITH COVID-19 MANISHKUMAR PATEL GLORIA HONG BERNADETTE SCHMIDT LAITH AL-JANABI RADHA KISHAN ADUSUMILLI JURGENA TUSHA PADMINI GIRI AND SARWAN KUMAR PURPOSE: It is understood that COVID-19 creates a cytokine storm, which ultimately leads to patient demise. A key antioxidant, Vitamin C (ascorbic acid), has been shown to decrease the production of cytokines leading to benefits in sepsis secondary to both viral and bacterial infections. By utilizing the known paradigm of suppressing the cytokine release, some recently emerging studies have shown mortality benefit with intravenous ascorbic acid when used in COVID-19 patients, however, there appears to be less information regarding ascorbic acid benefits when given via the oral route. Our study observed the mortality and extubation rate in COVID-19 patients receiving oral ascorbic acid. METHODS: A retrospective single-center cohort study was used to design the project. Patients who met the inclusion criteria were those who were admitted to our hospital for COVID-19 related symptoms and also tested positive for COVID-19 by a nasopharyngeal swab. The patients were divided into two groups of those who received a course of oral ascorbic acid and those who did not receive ascorbic acid. Those in the ascorbic acid group received daily oral doses that ranged from 500 mg to 1500 mg. Patients who received intravenous ascorbic acid were excluded. The primary outcome analyzed was the overall mortality rate, while secondary outcomes analyzed were the extubation rate and mortality rate in ICU patients. CONCLUSIONS: Our study found that COVID-19 patients receiving oral ascorbic acid had a statistically insignificant tendency toward decreased overall mortality, increased extubation rate, and decreased ICU mortality compared to the control group. The role of ascorbic acid in COVID-19 patients has not been clearly defined by clinical trials. With the low side effect profile, it has been administered in higher doses in intravenous form frequently in many hospitals with anecdotal evidence showing benefit. In our study, it was observed that patients were given oral ascorbic acid at a lesser dose than would be given if in the intravenous ascorbic acid form. CLINICAL IMPLICATIONS: Our observational study showed even when ascorbic acid is administered in oral form as an adjunct to COVID-19 therapy, it is associated with a mortality benefit and improved extubation rate. DISCLOSURES: No relevant relationships by Radha Kishan Adusumilli, source¼Web Response No relevant relationships by Laith Al-janabi, source¼Web Response No relevant relationships by Padmini Giri, source¼Web Response No relevant relationships by Gloria Hong, source¼Web Response No relevant relationships by Sarwan Kumar, source¼Web Response No relevant relationships by Manishkumar Patel, source¼Web Response No relevant relationships by Bernadette Schmidt, source¼Web Response No relevant relationships by Jurgena Tusha, source¼Web Response DOI: Copyright ª 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved. 325A CHEST INFECTIONS RESULTS: Of the total of 210 patients, 176 patients met our inclusion criteria. Of these, 96 patients were in the ascorbic acid group, including..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop